Retrospective study of sacral neuromodulator implantations in a French hospital center: Lifespan and hospital costs assessment
ConclusionsThe InterStim ™ II lifespan is shorter than the first-generation device. This is associated with an increase of the long-term hospital costs. Additional information about the new neuromodulator will be required to choose the most appropriate IPG for the patient while optimizing the costs.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Brain | France Health | Gastroenterology | Health Management | Incontinence | International Medicine & Public Health | Medical Devices | Neurology | Neurosurgery | Statistics | Study